Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR.

Drug Alcohol Depend. 2013 Oct 1;132(3):674-80. doi: 10.1016/j.drugalcdep.2013.04.021.

2.

[A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].

Krupitsky EM, Blokhina EA, Zvartau EE, Verbitskaya VE, Bushara EM, Tiurina AA, Palatkin VY, Yaroslavtseva TS, Burakov AM, Masalov DV, Romanova TN, Grininko AY, Sinha R, Kosten T.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(10):39-46. Russian.

PMID:
26525620
3.

Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Slavina T, Pecoraro A, Woody GE.

Arch Gen Psychiatry. 2012 Sep;69(9):973-81. doi: 10.1001/archgenpsychiatry.2012.1a.

4.

Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

Sullivan MA, Bisaga A, Mariani JJ, Glass A, Levin FR, Comer SD, Nunes EV.

Drug Alcohol Depend. 2013 Nov 1;133(1):80-5. doi: 10.1016/j.drugalcdep.2013.05.030.

5.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
6.

A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.

Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV.

Drug Alcohol Depend. 2011 Dec 1;119(1-2):e23-9. doi: 10.1016/j.drugalcdep.2011.05.019.

7.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.

Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013.

8.

Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

Syed YY, Keating GM.

CNS Drugs. 2013 Oct;27(10):851-61. doi: 10.1007/s40263-013-0110-x. Review.

PMID:
24018540
9.

[The use of different forms of naltrexone in the treatment of opioid dependence].

Krupitskiĭ EM, Zvartau EE, Blokhina EA, Woody G.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(11 Pt 2):66-72. Russian.

PMID:
22611701
10.

[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].

Krupitskiĭ EM, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Blokhina EA, Silverman BL.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(5 Pt 2):3-11. Russian.

PMID:
22951790
11.

Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.

Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.

J Subst Abuse Treat. 2006 Dec;31(4):319-28.

PMID:
17084785
12.

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Carpenter KM, Mariani JJ, Levin FR, Nunes EV.

J Subst Abuse Treat. 2014 May-Jun;46(5):546-52. doi: 10.1016/j.jsat.2014.01.005.

13.

Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.

Sinha R, Kimmerling A, Doebrick C, Kosten TR.

Psychopharmacology (Berl). 2007 Mar;190(4):569-74.

PMID:
17136399
14.
15.

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?

Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR.

J Addict Med. 2015 May-Jun;9(3):238-43. doi: 10.1097/ADM.0000000000000125.

16.

[Limited role of naltrexone in the treatment of opiate addiction].

van Brussel GH.

Ned Tijdschr Geneeskd. 2001 Jul 28;145(30):1452-6. Review. Dutch.

PMID:
11503313
17.

Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings.

Fox HC, Seo D, Tuit K, Hansen J, Kimmerling A, Morgan PT, Sinha R.

J Psychopharmacol. 2012 Jul;26(7):958-72. doi: 10.1177/0269881111430746.

18.

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL.

Addiction. 2013 Sep;108(9):1628-37. doi: 10.1111/add.12208.

PMID:
23701526
19.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
20.

Naltrexone for heroin dependence treatment in St. Petersburg, Russia.

Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.

J Subst Abuse Treat. 2004 Jun;26(4):285-94.

PMID:
15182893

Supplemental Content

Support Center